News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) Partners With the Sabin Vaccine Institute in an Effort to Develop Vaccines for Neglected Tropical Diseases


9/27/2012 4:20:14 PM

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a partnership agreement to supply the Sabin Vaccine Institute (Headquarters: Washington D.C., President: Dr. Peter Hotez, "Sabin") with E6020, an in-house developed adjuvant that enhances the immune effects of vaccines, as well as all relevant information pertaining to the compound free of charge, to support the development of vaccines for two neglected tropical diseases (NTDs) - Chagas disease and leishmaniasis. E6020 stimulates the body's immune system via TLR4 (Toll-like receptor 4), a receptor that plays a key role in the body's innate immune system., and is expected to be used in a broad range of antigen vaccines to enhance vaccine efficacy.

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES